0.58% 0.0679

Astria Therapeutics Inc (ATXS)

Astria Therapeutics Inc 주식(ATXS)의 최신 뉴스

Astria Therapeutics Inc (ATXS)

Astria Therapeutics Inc 주식(ATXS)의 최신 뉴스

ClariVest Asset Management LLC Makes New $731,000 Investment in Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat

Where are the Opportunities in (ATXS) - Stock Traders Daily

Astria Therapeutics (NASDAQ:ATXS) Stock Price Down 5.9% - MarketBeat

Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Bought by Panagora Asset Management Inc. - Defense World

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance UK

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Is Astria Therapeutics Inc (ATXS) worth investing in despite its overvalued state? - US Post News

Astria Therapeutics, Inc. (NASDAQ:ATXS) Sees Significant Growth in Short Interest - MarketBeat

Astria Therapeutics to Present at Upcoming Bradykinin Symposium - Business Wire

Astria Therapeutics to Present at Upcoming Bradykinin Symposium - StockTitan

Astria Therapeutics to Participate in Upcoming Morgan Stanley 22nd Annual Global Healthcare Conference - Business Wire

(ATXS) Trading Advice - Stock Traders Daily

Analyzing Astria Therapeutics Inc (ATXS) After Recent Trading Activity - Knox Daily

Astria Therapeutics (ATXS) – Investment Analysts’ Weekly Ratings Updates - Defense World

Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives $25.20 Consensus PT from Analysts - Defense World

Price T Rowe Associates Inc. MD Buys Shares of 14,203 Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World

Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat

Astria Therapeutics (NASDAQ:ATXS) Upgraded at Evercore ISI - MarketBeat

Astria Therapeutics, Inc. (NASDAQ:ATXS) Forecasted to Post Q3 2024 Earnings of ($0.45) Per Share - Defense World

Q3 2024 EPS Estimates for Astria Therapeutics, Inc. Decreased by HC Wainwright (NASDAQ:ATXS) - MarketBeat

Q3 2024 EPS Estimates for Astria Therapeutics, Inc. Decreased by HC Wainwright (NASDAQ:ATXS) - Defense World

Astria Therapeutics (NASDAQ:ATXS) Trading Down 2.8% - MarketBeat

Astria Therapeutics (NASDAQ:ATXS) Given Outperform Rating at Wedbush - Defense World

Astria Therapeutics (NASDAQ:ATXS) Price Target Raised to $26.00 at Oppenheimer - Defense World

Astria Therapeutics (NASDAQ:ATXS) Releases Earnings Results, Misses Estimates By $0.05 EPS - Defense World

Astria Therapeutics (NASDAQ:ATXS) Given Buy Rating at HC Wainwright - Defense World

Astria Therapeutics (NASDAQ:ATXS) Shares Gap Up Following Analyst Upgrade - Defense World

Astria Therapeutics (NASDAQ:ATXS) Shares Gap Up on Analyst Upgrade - MarketBeat

Astria Therapeutics (NASDAQ:ATXS) Given "Outperform" Rating at Wedbush - MarketBeat

Astria Therapeutics stock target raised by Oppenheimer on clinical progress - Investing.com Canada

Astria Therapeutics partners with Ypsomed for autoinjector development By Investing.com - Investing.com Australia

Astria Therapeutics (NASDAQ:ATXS) Posts Quarterly Earnings Results, Misses Expectations By $0.05 EPS - MarketBeat

TD Cowen keeps Buy rating on Astria Therapeutics stock, highlights STAR-0215's Q6M dosing - Investing.com UK

Astria Therapeutics taps Ypsomed’s autoinjector for hereditary angioedema drug delivery - Yahoo Finance

Astria Therapeutics (NASDAQ:ATXS) PT Raised to $26.00 - MarketBeat

Astria Therapeutics stock target raised by Oppenheimer on clinical progress - Investing.com UK

ATXS Stock Earnings: Astria Therapeutics Misses EPS for Q2 2024 - InvestorPlace

Astria Therapeutics partners with Ypsomed for autoinjector development - Investing.com

Astria Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update - Business Wire

Astria Therapeutics reports Q2 EPS (43c), consensus (38c) - TipRanks

Astria Therapeutics Chooses Ypsomed’s YpsoMate as the Injection Device for STAR-0215 for the Treatment of Hereditary Angioedema - StockTitan

Astria Therapeutics Chooses Ypsomed’s YpsoMate as the Injection Device for STAR-0215 for the Treatment of Hereditary Angioedema - Yahoo Finance

Vanguard Group Inc. Acquires 480,184 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World

Vanguard Group Inc. Raises Holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat

Astria Therapeutics to Participate in Upcoming 2024 Wedbush PacGrow Healthcare Conference - Business Wire

Tidal Investments LLC Buys New Holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan

Astria Therapeutics, Inc. (NASDAQ:ATXS) Short Interest Update - Defense World

Astria Therapeutics (NASDAQ:ATXS) Shares Gap Up to $11.93 - Defense World

Short Interest in Astria Therapeutics, Inc. (NASDAQ:ATXS) Decreases By 5.7% - MarketBeat

Astria Therapeutics (NASDAQ:ATXS) Earns Buy Rating from Analysts at TD Cowen - MarketBeat

TD Cowen Initiates Coverage on Astria Therapeutics (NASDAQ:ATXS) - Defense World

Astria Therapeutics initiated at 'Buy' on strong prospects for STAR-0215TD Cowen - Investing.com Canada

Astria Therapeutics initiated at 'Buy' on strong prospects for STAR-0215TD Cowen - Investing.com UK

(ATXS) Technical Data - Stock Traders Daily

Ameritas Investment Partners Inc. Boosts Stake in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World

A Guide To The Risks Of Investing In Astria Therapeutics Inc (ATXS) - Knox Daily

Oppenheimer & Co. Inc. Reduces Stock Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World

Astria Therapeutics (NASDAQ:ATXS) Stock Price Passes Above Fifty Day Moving Average of $9.43 - MarketBeat

Astria Therapeutics (NASDAQ:ATXS) Stock Price Crosses Above 50-Day Moving Average of $9.43 - Defense World

We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely - Simply Wall St

Results from Astria Therapeutics Inc (ATXS) show potential - US Post News

ATXS’s latest rating updates from top analysts. - Knox Daily

Astria Therapeutics Inc (ATXS) Stock: A Comprehensive 52-Week Review - The InvestChronicle

Astria Therapeutics (NASDAQ:ATXS) Shares Up 6% - MarketBeat

ATXS과 유사한 종목